Latest PMVP reports update at 2024-02-29: 2023 ∙ 2022 ∙ 2021

PMV Pharmaceuticals PMVP

$ 1.82 1.68%

PMV Pharmaceuticals Balance Sheet 2011-2024 | PMVP

Annual Balance Sheet PMV Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-24.4 M	-94.3 M	-161 M	-	-73.3 M	-30.3 M	-	-	-	-	-	-	-
Long Term Debt	12.4 M	13.4 M	10.8 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	852 K	528 K	403 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	169 M	107 M	-	-	-	-	-	-	-
Total Current Liabilities	14 M	10.8 M	12.2 M	6.41 M	-	-	-	-	-	-	-	-	-
Total Liabilities	26.5 M	24.3 M	23 M	6.41 M	174 M	110 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-310 M	-241 M	-168 M	-110 M	-75.4 M	-50.1 M	-	-	-	-	-	-	-
Total Assets	252 M	270 M	332 M	366 M	103 M	63.5 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	37.7 M	108 M	172 M	361 M	-	-	-	-	-	-	-	-	-
Book Value	226 M	246 M	309 M	359 M	-70.5 M	-46.1 M	-	-	-	-	-	-	-
Total Shareholders Equity	226 M	246 M	309 M	359 M	-70.5 M	-46.1 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet PMV Pharmaceuticals

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	12.7 M	13 M	13.2 M	13.4 M	12.1 M	12.2 M	11.5 M	10.8 M	10.7 M	10.6 M	302 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	23.4 M	24.4 M	23.8 M	24.3 M	23.8 M	23.6 M	23.2 M	23 M	19.2 M	18.1 M	6.1 M	6.41 M	6.41 M	6.41 M	6.41 M	4.57 M	4.57 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-294 M	-278 M	-260 M	-241 M	-222 M	-203 M	-186 M	-168 M	-149 M	-134 M	-121 M	-110 M	-110 M	-110 M	-110 M	-75.4 M	-75.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	261 M	242 M	254 M	270 M	285 M	301 M	315 M	332 M	344 M	356 M	354 M	366 M	366 M	366 M	366 M	103 M	103 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	52.1 M	68.2 M	143 M	108 M	99.8 M	87.1 M	116 M	172 M	177 M	189 M	209 M	361 M	361 M	361 M	361 M	73.3 M	73.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	238 M	218 M	230 M	246 M	261 M	277 M	292 M	309 M	325 M	338 M	348 M	359 M	359 M	359 M	359 M	98.5 M	98.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	238 M	218 M	230 M	246 M	261 M	277 M	292 M	309 M	325 M	338 M	348 M	359 M	359 M	359 M	359 M	-70.5 M	-70.5 M	-57.7 M	-51.9 M	-46.1 M	-	-	-	-29.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency